Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study | Synapse
March 3, 2026
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study
Key Points
Exposure-response relationship was observed between nivolumab and ipilimumab treatment and patient outcomes.
Nivolumab combined with ipilimumab led to improved overall survival in metastatic renal cell carcinoma patients.
Analysis conducted in a randomised phase 2 study setting across multiple treatment centers.
Findings highlight the importance of individualized dosing strategies for better outcomes based on biomarker responses.